Insmed | INSM - Cash And Equivalent

Stock Price
109.14
Daily Change
-6.48 -5.60%
Monthly
-23.57%
Yearly
60.22%
Q2 Forecast
106.95

Insmed reported $582.19M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
DBV Technologies USD 194.17M 124.33M Dec/2025
Gilead Sciences USD 7.56B 234M Dec/2025
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Novartis USD 9.56B 2.9B Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026